Phase I evaluation of NP137

By | Actualités

NETRIS Pharma announces the approval of Agence Nationale de Sécurité des Médicaments et produits de santé (ANSM) for the clinical evaluation of NP137, its first humanized monoclonal antibody targeting Netrin-1….

Read More

ANR granted the TROY program

By | News

NETRIS Pharma announces that ANR (Agence Nationale de la Recherche) granted the translational RHU TROY program aiming at Targeting dependence Receptors (DRs) in Oncology and hematologY. This program aims at…

Read More

BioEquity Europe 2015

By | Event

NETRIS Pharma will attend the BioEquity Europe 2015 meeting in Vienna, Austria (May 19th-20th). During the “Next Wave Companies” session, Stéphane Depil – CEO – will present NETRIS Pharma activities…

Read More

AACR Annual Meeting 2015

By | Event

NETRIS Pharma will attend the AACR Annual Meeting 2015 in Philadelphia, US (April 18th-22nd). For this occasion, NETRIS Pharma will present recent data regarding its first-in-class humanized anti-Netrin-1 antibody NP137,…

Read More

26th EORTC-NCI-AACR Symposium

By | Event
NETRIS Pharma will attend the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain. For this occasion, NETRIS Pharma will present the preclinical characteristics of NP137, its...
Read More